ArticleJournal of nanobiotechnology2021
A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Natural Product-Based Nanomedicine in the Treatment of Breast Cancer.Pharmaceutics · 2026Review
- Prognostic and Immunologic Characteristics of Head and Neck Squamous Cell Carcinoma Based on Disulfidptosis-Related lncRNAs.Molecular biotechnology · 2026Article
- Nanoparticle‑based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (Review).International journal of oncology · 2025Review
- Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses.BMC cancer · 2025Article
- MicroRNA-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects.Nanomedicine (London, England) · 2025Review
- Establishment of a prognostic signature and immune infiltration characteristics for uterine corpus endometrial carcinoma based on a disulfidptosis/ferroptosis-associated signature.Frontiers in immunology · 2025Article
- Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment.Frontiers in immunology · 2025Article
- A novel disulfidptosis-related prognostic gene signature and experimental validation identifyCancer biomarkers : section A of Disease markers · 2025Article
- Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer.Materials today. Bio · 2024Review
- Therapeutic and prognostic effect of disulfidptosis-related genes in lung adenocarcinoma.Heliyon · 2024Article
- Article
- Multi-Omics Insights into Disulfidptosis-Related Genes Reveal RPN1 as a Therapeutic Target for Liver Cancer.Biomolecules · 2024Article
- Article
- Article
- Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy.Frontiers in bioengineering and biotechnology · 2024Article
- Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy.International journal of biological sciences · 2023Review
- Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.Frontiers in endocrinology · 2023Article
- Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.International journal of molecular sciences · 2022Review
- Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.Cancers · 2022Review
- Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.American journal of cancer research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTriple negative breast cancer (TNBC) is one of the most biologically aggressive breast cancers and lacks effective treatment options, resulting in a poor prognosis. Therefore, studies aiming to explore new therapeutic strategies for advanced TNBC are urgently needed. According to recent studies, microRNA-124 (miR124) not only inhibits tumour growth but also increases the sensitivity of TNBC to paclitaxel (PTX), suggesting that a platform combining PTX and miR124 may be an advanced solution for TNBC.
resultsHerein, we constructed a stepped cleavable calcium phosphate composite lipid nanosystem (CaP/LNS) to codeliver PTX and miR124 (PTX/miR124-NP). PTX/miR124-NP exhibited superior tumor microenvironment responsive ability, in which the surface PEG layer was shed in the mildly acidic environment of tumor tissues and exposed oligomeric hyaluronic acid (o-HA) facilitated the cellular uptake of CaP/LNS by targeting the CD44 receptor on the surface of tumor cells. Inside tumour cells, o-HA detached from CaP/LNS due to the reduction of disulfide bonds by glutathione (GSH) and inhibited tumour metastasis. Then, PTX and miR124 were sequentially released from CaP/LNS and exerted synergistic antitumour effects by reversing the Epithelial-Mesenchymal Transition (EMT) process in MDA-MB-231 cells. Moreover, PTX/miR124-NP showed significant antitumour efficiency and excellent safety in mice bearing MDA-MB-231 tumours.
conclusionBased on these results, the codelivery of PTX and miR124 by the CaP/LNS nanosystem might be a promising therapeutic strategy for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.